SAN DIEGO, April 2, 2011 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC) today announced its participation in the 60th Annual Scientific Session of the American College of Cardiology (ACC) from April 2nd to April 5th, 2011 in New Orleans.
"Volcano continues to lead the industry in partnering with physicians to deliver Precision Guided Therapy to patients worldwide," commented Scott Huennekens, President and CEO of Volcano. "Our comprehensive suite of guidance technologies provides the precise insight that physicians need to make treatment decisions that result in a truly personalized treatment path for their patients. We are excited to highlight our innovative devices that have already impacted more than one million patients, contributing to their chances of better outcomes, shorter hospital stays, lower costs, and, typically, a higher quality of life."
Volcano will highlight its suite of precision guided therapy technologies, which includes integrated cath lab systems, coronary and peripheral IVUS catheters, and physiology guide wires measuring both pressure and flow. These products, which are all available for sale in the U.S. and/or Europe, include:
- The PrimeWire PRESTIGE™, the next generation Fractional Flow Reserve (FFR) wire with a familiar frontline tip, better torque and more support for challenging lesions;
- The Eagle Eye® Platinum, the #1 digital IVUS catheter in the world, which provides exceptional deliverability, the convenience of radiopaque markers, and three imaging modalities including grayscale IVUS, VH® IVUS and ChromaFlo®;
- The VIBE® RX Vascular Imaging Balloon Catheter, which can quickly access, prepare, and assess challenging lesions and provide precise, targeted balloon dilatation with immediate confirmation of interventional results; and
- The s5™/s5i™ 3.2.1 software, which streamlines the workflow for both IVUS and FFR procedures and is compatible with more than 3,700 Volcano systems installed worldwide.
All products will be available for demonstration at Booth #4034. Volcano's technology will also be on display in other booths, including GE Healthcare, Siemens Healthcare, Philips Healthcare, and Toshiba America Medical Systems. In addition, Volcano will highlight its extensive pipeline of imaging and therapy products still in development, including Optical Coherence Tomography (OCT), Micro Catheters, and Forward Looking Imaging including IVUS and ICE applications.
"Volcano is focused on providing quality guidance solutions for our customers, and allowing physicians to choose which tool is the most appropriate for that particular patient's presentation," added Joe Burnett, Volcano's Executive Vice President of Marketing. "This year at ACC, we are focusing much of our training and education efforts around bifurcation disease, which remains a large, unmet clinical need, with repeat revascularization rates routinely higher than 10%. Physicians are continuously looking for ways to improve the level of care they provide in these complex lesions, and there are more than 20 presentations at the ACC this year focused on this topic. We believe that by assessing bifurcation lesions with tools like IVUS and FFR, a physician can more precisely decide on their main branch and side branch strategy, guide the placement of the stent, and then confirm the function of that side branch while the patient is still on the table. Volcano is the only company that can provide both of these technologies on the same product platform seamlessly integrated into the Cath Lab for ease of use and prompt diagnostics."
About Volcano Corporation
Volcano Corporation is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Our products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information - using sound and light as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered "forward-looking statements." including statements regarding the potential benefits of the products and procedures described above, further development and expansion, regulatory approval, commercial release and market adoption of the company's technology, and the impact of clinical and other technical data. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause Volcano's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ include the pace and extent of market adoption of the company's products and technologies, growth strategies, timing and achievement of product development milestones, outcome of ongoing litigation, the impact and benefits of market development, product introductions, unexpected new data, safety and technical issues, market conditions, and other risks inherent to medical device development and commercialization. These and additional risks and uncertainties are more fully described in Volcano's filings made with the Securities and Exchange Commission, including our recent annual report on Form 10-K. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
SOURCE Volcano Corporation